Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

APA Group Rights Issue: EPS Dilution and Rich Valuation Despite Stable Business

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>As part of the APA Group entitlement offering book runners launched the retail shortfall bookbuild today. We have covered the fundamentals of the deal in our previous note: <a href="https://www.smartkarma.com/insights/apa-group-rights-issue-eps-dilution-and-rich-valuation-despite-stable-business" target="_blank" data-smartkarma-citation="insights:17937">APA Group Rights Issue: EPS Dilution and Rich Valuation Despite Stable Business</a> . In this insight, we intend to provide a quick update on the retail shortfall tranche. </p><h2>The Deal</h2><ul>
<li>Retail shortfall offer: 15 million entitlements</li>
<li>Pricing: Starts from AUD7.7 per share with 5 cents increment</li>
<li>Settlement of retail entitlement offer…</li>
</ul>

As part of the APA Group entitlement offering book runners launched the retail shortfall bookbuild today. We have covered the fundamentals of the deal in our previous note: APA Group Rights Issue: EPS Dilution and Rich Valuation Despite Stable Business . In this insight, we intend to provide a quick update on the retail shortfall tranche. The Deal
Retail shortfall offer: 15 million entitlements
Pricing: Starts from AUD7.7 per share with 5 cents increment
Settlement of retail entitlement offer…


APA Group

APA Group Retail Short Fall Update